Abstract | OBJECTIVES: METHODS: KALLISTO (NCT01868477) was a randomized, open-label, multicenter, phase II study. Lower-risk MDS patients received deferasirox at 10 mg/kg/d (dispersible tablets) or 7 mg/kg/d (film-coated tablets) plus erythropoietin (n = 11), or erythropoietin alone (n = 12) for 24 weeks. The primary endpoint was the between-group difference in erythroid response within 12 weeks. RESULTS: CONCLUSIONS: In this small pilot study, combining low-dose deferasirox with erythropoietin did not improve erythroid response. It remains of interest to investigate early chelation approaches with even lower deferasirox doses plus erythropoietin in lower-risk MDS patients before the onset of transfusion dependence.
|
Authors | Norbert Gattermann, Rosa Coll, Lutz Jacobasch, Allameddine Allameddine, Amin Azmon, Laurie DeBonnett, Andreas Bruederle, Jie Jin, KALLISTO study investigators |
Journal | European journal of haematology
(Eur J Haematol)
(May 19 2018)
ISSN: 1600-0609 [Electronic] England |
PMID | 29777631
(Publication Type: Journal Article)
|
Copyright | © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |